{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:27:19Z","timestamp":1786116439209,"version":"build-2736575974"},"reference-count":53,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006603","name":"BMBF","doi-asserted-by":"publisher","award":["16GW0285"],"award-info":[{"award-number":["16GW0285"]}],"id":[{"id":"10.13039\/501100006603","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Background: Increasing resistance against protein kinase inhibitors used in cancer therapies enforces the search for novel target structures to be addressed with favourable small-molecule inhibitors. One of these novel target structures is the tyrosine kinase Brk that is known to play a prominent role in breast cancer progression. Moreover, Brk overexpression in various kinds of cancer is associated with poor outcomes, making Brk an interesting target structure for potential treatment. So far, no class of promising Brk inhibitors has been identified. Methods: We synthesized novel functionalized pyrrolopyridines in one- and two-step reactions under substitution of the molecular scaffold and the 4-aniline residue, respectively. They were evaluated as inhibitors of Brk and HER2 in a radiolabelled enzyme assay. Results: The most favourable substituents for Brk inhibitory activity at the aniline residues were 3-hydroxy functions combined with either bromo or nitro substituents at the molecular scaffold. Those compounds, as well as bromo- and nitro-substituted compounds, also showed the best HER2 inhibitor activities. Conclusions: Novel pyrrolopyridines were discovered to be a promising class of nanomolar Brk inhibitor with additional HER2 activities to further strengthen Brk inhibitory activity in prospective anticancer therapies. Thus, the first class of Brk inhibitors could be identified.<\/jats:p>","DOI":"10.3390\/molecules31152730","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T09:46:38Z","timestamp":1786009598000},"page":"2730","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel Functionalized Pyrrolopyridines to Target Brk"],"prefix":"10.3390","volume":"31","author":[{"given":"Erik","family":"Schmidt","sequence":"first","affiliation":[{"name":"Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Wolfgang-Langenbeck-Str. 4, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannis","family":"von Veh","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Wolfgang-Langenbeck-Str. 4, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9261-9316","authenticated-orcid":false,"given":"Anne-Christin","family":"Sarnow","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Wolfgang-Langenbeck-Str. 4, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5985-9261","authenticated-orcid":false,"given":"Wolfgang","family":"Sippl","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Wolfgang-Langenbeck-Str. 4, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8677-9511","authenticated-orcid":false,"given":"Julian","family":"Kowalski","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Wolfgang-Langenbeck-Str. 4, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6540-6357","authenticated-orcid":false,"given":"Niels","family":"Heise","sequence":"additional","affiliation":[{"name":"Institute of Chemistry, Martin-Luther-University Halle-Wittenberg, Kurt-Mothes-Str. 3, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Totzke","sequence":"additional","affiliation":[{"name":"Reaction Biology Europe GmbH, Engesserstr. 4, 79108 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hilgeroth","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Wolfgang-Langenbeck-Str. 4, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Dell\u2019Aversana, C., Sarno, F., Benedetti, R., Megchelenbrink, W.L., and Capetta, D. (2024). Cancer Therapy Resistance: Choosing Kinase Inhibitors. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16030373"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.acr.2018.02.003","article-title":"Acquired Resistance to Drug Targeting Tyrosine Kinases","volume":"138","author":"Rosenzweig","year":"2018","journal-title":"Adv. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targetd cancer therapies: Progress, challenges and future directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: Progress and future directions","volume":"20","author":"Choen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/0008-5472.CAN-17-2291","article-title":"New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome","volume":"78","author":"Wilson","year":"2018","journal-title":"Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Cicenas, J., Zalyte, E., Bairoch, A., and Gaudet, P. (2018). Kinases and Cancer. Cancers, 10.","DOI":"10.3390\/cancers10030063"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bansal, I., Pandey, A.K., and Ruwali, M. (2023). Small-molecule inhibitors of kinases in breast cancer therapy: Recent advances, opportunities, and challenges. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1244597"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: Molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_9","first-page":"2608","article-title":"Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia","volume":"22","author":"Monaldi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"188432","DOI":"10.1016\/j.bbcan.2020.188432","article-title":"Targeting Protein Tyrosine Kinase 6 in Cancer","volume":"1874","author":"Gilic","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_11","first-page":"2383","article-title":"Cloning and Characterization of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast cancer tumours","volume":"9","author":"Mitchell","year":"1994","journal-title":"Oncogene"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"34634","DOI":"10.1074\/jbc.M203877200","article-title":"Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and autoinhibition","volume":"277","author":"Qiu","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1038\/sj.onc.1209501","article-title":"Identification of STAT3 as a specific substrate of breast tumor kinase","volume":"25","author":"Liu","year":"2006","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/bcr1794","article-title":"Signal Transducer and activator of transcription 5b: A new target of breast tumor kinase\/protein tyrosine kinase 6","volume":"9","author":"Weaver","year":"2007","journal-title":"Breast Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1242\/jcs.053264","article-title":"Identification of beta-catenin as a target of the intracellular tyrosine kinase PTK6","volume":"123","author":"Gierut","year":"2010","journal-title":"J. Cell Sci."},{"key":"ref_16","first-page":"39","article-title":"Tracing the footprints of the breast cancer oncogene BRK\u2014Past till present","volume":"1856","author":"Goel","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.coph.2010.08.007","article-title":"Brk\/PTK6 signaling in normal and cancer cell models","volume":"10","author":"Ostrander","year":"2010","journal-title":"Curr. Opin. Pharmakol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.4161\/cbt.29822","article-title":"HIF-1 alpha-independent Hypoxia-induced rapid PTK6 stabilization is associated with increased motility and invasion","volume":"15","author":"Pires","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/bcr2622","article-title":"Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells","volume":"12","author":"Castro","year":"2010","journal-title":"Breast Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13058-015-0594-z","article-title":"PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim","volume":"17","author":"Ito","year":"2015","journal-title":"Breast Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/0008-5472.CAN-13-0443","article-title":"PTK6 activation at the membrane regulates epithelial-mesenchymal transition in prostate cancer","volume":"73","author":"Zheng","year":"2013","journal-title":"Cancer Res."},{"key":"ref_22","first-page":"1","article-title":"Protein tyrosine kinase 6 signaling in prostate cancer","volume":"8","author":"Alwanian","year":"2020","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_23","first-page":"66","article-title":"Building a better understanding of the intracellular tyrosine kinase PTK6\u2014BRK by BRK","volume":"1806","author":"Brauer","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1053\/j.gastro.2011.06.071","article-title":"Disruption of the mouse protein tyrosine kinase 6 gene prevents STAT3 activation and confers resistance to azoxymethane","volume":"141","author":"Gierut","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s13277-011-0188-z","article-title":"Detection of Brk expression in non-small cell lung cancer: Clinicopathological relevance","volume":"32","author":"Fan","year":"2011","journal-title":"Tumor Biol."},{"key":"ref_26","first-page":"181","article-title":"Expression of protein tyrosine kinase 6 (PTK6) in nonsmall cell lung cancer and their clinical and prognostic significance","volume":"6","author":"Zhao","year":"2013","journal-title":"Onco Targets Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/1541-7786.MCR-15-0034","article-title":"PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-phase and Enhancing DNA-damage in Pancreatic Cancer","volume":"13","author":"Ono","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1038\/s41388-020-1275-7","article-title":"Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression","volume":"39","author":"Chandrashekar","year":"2020","journal-title":"Oncogene"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1158\/1541-7786.MCR-07-2001","article-title":"BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells","volume":"6","author":"Sala","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic Profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nchembio.332","article-title":"A chemical and phosphoproteomic characterization of dasatinib action in lung cancer","volume":"6","author":"Li","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/17460441.2016.1201057","article-title":"The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma","volume":"11","author":"Kim","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"116210","DOI":"10.1016\/j.ejmech.2024.116210","article-title":"Design, synthesis and evaluation of C-5 substituted pyrrolopyridine derivatives as potent Janus Kinase 1 inhibitors with excellent selectivity","volume":"267","author":"Chen","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1158\/0008-5472.CAN-06-3409","article-title":"Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells","volume":"67","author":"Ostrander","year":"2007","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevOncog.v17.i1.20","article-title":"Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: Mechanisms and clinical implications","volume":"17","author":"Rexer","year":"2012","journal-title":"Crit. Rev. Oncog."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.62347\/KIVS3169","article-title":"Receptor tyrosine kinases in breast cancer treatment: Unraveling the potential","volume":"14","author":"Qi","year":"2024","journal-title":"Am. J. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"15906","DOI":"10.1021\/acs.jmedchem.0c01647","article-title":"HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability","volume":"63","author":"Elwaie","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Ligand preparation: Parameters, protocols, and influence on virtual screening enrichments","volume":"25","author":"Sastry","year":"2013","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref_39","unstructured":"(2024). Schr\u00f6dinger Release 2025-2: Protein Preparation Workflow, Schr\u00f6dinger, LLC."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"11225","DOI":"10.1021\/ja9621760","article-title":"Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids","volume":"118","author":"Jorgensen","year":"1996","journal-title":"J. Am. Chem. Soc."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1021\/ja00214a001","article-title":"The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin","volume":"110","author":"Jorgensen","year":"1988","journal-title":"J. Am. Chem. Soc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1021\/ct900587b","article-title":"Prediction of Absolute Solvation Free Energies using Molecular Dynamics Free Energy Perturbation and the OPLS Force Field","volume":"6","author":"Shivakumar","year":"2010","journal-title":"J. Chem. Theory Comput."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space","volume":"17","author":"Lu","year":"2021","journal-title":"J. Chem. Theory Comput."},{"key":"ref_44","unstructured":"(2025). Schr\u00f6dinger Release 2025-2: LigPrep, Schr\u00f6dinger, LLC."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1021\/acs.jctc.3c00044","article-title":"Epik: pKa and Protonation State Prediction through Machine Learning","volume":"19","author":"Johnston","year":"2023","journal-title":"J. Chem. Theory Comput."},{"key":"ref_46","unstructured":"(2025). Schr\u00f6dinger Release 2025-2: ConfGen, Schr\u00f6dinger, LLC."},{"key":"ref_47","unstructured":"(2025). Schr\u00f6dinger Release 2025-2: Glide, Schr\u00f6dinger, LLC."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide:\u2009 A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra Precision Glide:\u2009 Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein\u2013Ligand Complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide:\u2009 A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7106","DOI":"10.1021\/acs.jctc.1c00810","article-title":"Efficient Exploration of Chemical Space with Docking and Deep Learning","volume":"17","author":"Yang","year":"2021","journal-title":"J. Chem. Theory Comput."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Passaro, S., Corso, G., Wohlwend, J., Reveiz, M., Thaler, S., Somnath, V.R., Getz, N., Portnoi, T., Roy, J., and Stark, H. (2025). Boltz-2: Towards Accurate and Efficient Binding Affinity Prediction. bioRxiv.","DOI":"10.1101\/2025.06.14.659707"},{"key":"ref_53","unstructured":"(2025). Schr\u00f6dinger Release 2025-2: QikProp, Schr\u00f6dinger, LLC."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/15\/2730\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T09:46:48Z","timestamp":1786009608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/15\/2730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":53,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["molecules31152730"],"URL":"https:\/\/doi.org\/10.3390\/molecules31152730","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]}}}